Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: a 6-year follow-up
✍ Scribed by Andrew Barker; Roy Jones; Jackie Prior; Keith Wesnes
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 102 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
✦ Synopsis
Objective. To determine if scopolamine-induced cognitive impairment in healthy elderly people predicts cognitive decline 6 years later.
Design. Prospective cohort study. Setting. Elderly care research unit. Participants. Healthy elderly people who were part of a volunteer panel of research subjects. Interventions. Scopolamine 0.2 mg administered subcutaneously at baseline. Main outcome measures. Cognitive drug research computerized cognitive testing battery pre-and post-scopolamine, with repeat testing over 6 years later.
Main results. 16/24 subjects were retested. Although marked decrements in cognitive functioning were seen with scopolamine, there was little change in performance over 6 years, and no signi®cant association was seen between scopolamine-induced decrement and change over time.
Conclusions. The scopolamine challenge test is not likely to play a role in the preclinical diagnosis of Alzheimer's disease.